- Anindya Chatterjee Brings Over Thirteen Years of Capital Markets
Experience to AOBO - - New Role Emphasizes Strategic Growth Plan and Capital Markets Interaction
NEW YORK, June 9 /PRNewswire-FirstCall/ -- American Oriental Bioengineering, Inc. (NYSE: AOB) ("AOB" or "the Company"), a pharmaceutical company dedicated to improving health through the development, manufacture and commercialization of a broad range of prescription and over the counter ("OTC") products in China, today announced the appointment of Anindya Chatterjee to Chief Strategy Officer, effective May 23, 2008. Based in New York, Anindya Chatterjee will report to Lily Li, Chief Financial Officer, Chief Operating Officer and co-founder of the Company.
Anindya Chatterjee will work closely with AOBO's management team to shape and execute the Company's core growth initiatives, including acquisition-led expansion and capital markets strategy. Further, he will also serve as the Company's interface with the investment community, playing a crucial role in enhancing investor communications and transparency.
Anindya Chatterjee brings more than thirteen years of capital markets
experience to AOBO. He was previously a Managing Director in equity
research at Jefferies & Co, where he headed Emerging Asian (China & India)
equity research. He was also a Strategist and Economist focused on
Non-Japan Asia for Bear Stearns & Company in Hong Kong. He held similar
positions at IDEA INC. in New York, and NatWest Markets in Singapore, where
he was the Emerging Markets Strategist and Regional Economist and Equity
Strategist, respectively. He also was the Head of Research at ANZ
Investment Bank in India, an
|SOURCE American Oriental Bioengineering, Inc.|
Copyright©2008 PR Newswire.
All rights reserved